A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet<sup>®</sup>/Daivobet<sup>®</sup>/Taclonex<sup>®</sup>) in the treatment of psoriasis vulgaris
A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet<sup>®</sup>/Daivobet<sup>®</sup>/Taclonex<sup>®</sup>) in the treatment of psoriasis vulgaris is a paper indexed in ScholarIQ from OpenAlex.
How many citations does A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet<sup>®</sup>/Daivobet<sup>®</sup>/Taclonex<sup>®</sup>) in the treatment of psoriasis vulgaris have?
A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet<sup>®</sup>/Daivobet<sup>®</sup>/Taclonex<sup>®</sup>) in the treatment of psoriasis vulgaris has 139 citations in the OpenAlex counts ScholarIQ stores.
When was A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet<sup>®</sup>/Daivobet<sup>®</sup>/Taclonex<sup>®</sup>) in the treatment of psoriasis vulgaris published?
A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet<sup>®</sup>/Daivobet<sup>®</sup>/Taclonex<sup>®</sup>) in the treatment of psoriasis vulgaris has 2006 year in the ScholarIQ index.
What is the open-access status of A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet<sup>®</sup>/Daivobet<sup>®</sup>/Taclonex<sup>®</sup>) in the treatment of psoriasis vulgaris?
A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet<sup>®</sup>/Daivobet<sup>®</sup>/Taclonex<sup>®</sup>) in the treatment of psoriasis vulgaris has closed oa status in the ScholarIQ index.
What is the DOI of A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet<sup>®</sup>/Daivobet<sup>®</sup>/Taclonex<sup>®</sup>) in the treatment of psoriasis vulgaris?
The DOI for A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet<sup>®</sup>/Daivobet<sup>®</sup>/Taclonex<sup>®</sup>) in the treatment of psoriasis vulgaris is on the source record.
What is the PMID of A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet<sup>®</sup>/Daivobet<sup>®</sup>/Taclonex<sup>®</sup>) in the treatment of psoriasis vulgaris?
The PMID for A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet<sup>®</sup>/Daivobet<sup>®</sup>/Taclonex<sup>®</sup>) in the treatment of psoriasis vulgaris is on the source record.
What is the OpenAlex record for A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet<sup>®</sup>/Daivobet<sup>®</sup>/Taclonex<sup>®</sup>) in the treatment of psoriasis vulgaris?
The OpenAlex for A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet<sup>®</sup>/Daivobet<sup>®</sup>/Taclonex<sup>®</sup>) in the treatment of psoriasis vulgaris is on the source record.